Multiple pulmonary sclerosing pneumocytoma, based on a study of 36 cases worldwide

• Published in: Scientific reports Vol. 14; no. 1; p. 12242
• Main Authors: He, Pan, Wang, Jianwei, Guo, Jiong, Li, Shunqi, Zhang, Weidong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28-05-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4028/546; 692/420/755; 692/499; 692/699/1785; 692/700/139/422; Adult; Aged; Diagnosis; Female; Humanities and Social Sciences; Humans; Lung Neoplasms - diagnosis; Lung Neoplasms - epidemiology; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Metastases; Middle Aged; multidisciplinary; Multiple tumor; Patients; Prognosis; Pulmonary Sclerosing Hemangioma - diagnosis; Pulmonary Sclerosing Hemangioma - epidemiology; Pulmonary Sclerosing Hemangioma - pathology; Pulmonary Sclerosing Hemangioma - surgery; Pulmonary sclerosing pneumocytoma; Science; Science (multidisciplinary); Thoracic surgery; Treatment and diagnosis; Tumors; Multiple tumor; Treatment and diagnosis; Pulmonary sclerosing pneumocytoma
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-63185-7

To analyze the clinical characteristics and to improve clinicians’ understanding of multiple pulmonary sclerosing pneumocytoma (PSP) patients. A total of 36 PSP patients with multiple tumor characteristics were identified from the literature search. They were compared with 43 solitary PSP patients diagnosed and treated in our hospital in the past 5 years. Thus, the pathogenesis, clinical symptoms, diagnosis methods, treatment strategies, and prognosis of pulmonary sclerosing pneumocytoma (PSP) patients with multiple tumors were explored. Patients with multiple PSP are mostly distributed in Asia (88.89%) and are females (83.33%). PSP can be located in any one lobe (19.44%), or grow across ipsilateral lobes (44.44%), or even, bilateral lobes (36.11%). It can be accompanied by metastasis (9.09%) and is prone to misdiagnosis (27.78%). Compared with solitary PSP, the occurrence age of multiple PSP was younger (mean ± standard deviation [SD]: 40.36 ± 18.12: 51.28 ± 12.74 years), but there was no significant difference in sex, tumor size (mean ± SD: 43.54 ± 46.18: 30.56 ± 17.62 mm), or symptoms. Individualized surgical resection is required for treatment, including pneumonectomy (17.65%), lobectomy (23.53%), subpulmonary lobectomy (38.24%), or combined lobectomy (5.88%). Multiple PSP is relatively rare. Surgical resection within a limited time should be the main treatment for such patients. The prognosis of patients with multiple PSP is generally good, but inappropriate diagnosis and treatment plans may lead to poor prognosis.